Autolus Therapeutics (NASDAQ: AUTL) to cut 13% of staff, save $15M
Rhea-AI Filing Summary
Autolus Therapeutics plc is implementing a restructuring plan that includes a reduction in force affecting approximately 13% of its workforce, leading to estimated total restructuring charges of about $8 million, primarily for severance and related costs. The company expects to record a significant portion of these charges in the first half of 2026 and to substantially complete the workforce reduction by the third quarter of 2026.
Autolus projects that these actions will reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027. It confirmed financial guidance for full-year 2026 AUCATZYL net product revenue of $120 million to $135 million and, based on current plans, continues to expect its cash, cash equivalents and marketable securities to fund operations into the fourth quarter of 2027.
Positive
- None.
Negative
- None.
Insights
Autolus trades near‑term restructuring costs for longer‑term margin gains while reaffirming revenue and cash runway.
Autolus Therapeutics plans a workforce reduction of about 13%, driving estimated annualized operating expense savings of $15 million starting in 2027. The company expects roughly $8 million in restructuring charges, mainly severance, with most of the impact recognized in the first half of 2026.
The company maintained full‑year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million, suggesting the cost actions are primarily efficiency‑driven rather than tied to a guidance cut. Management also reiterated that existing and projected cash, cash equivalents and marketable securities should fund operations into the fourth quarter of 2027.
For investors, the key considerations are execution of the restructuring without disrupting commercial or pipeline efforts and whether the targeted $15 million annualized savings and revenue trajectory support the stated cash runway into late 2027. Subsequent filings and updates will clarify realized savings and any operational impacts.
8-K Event Classification
Key Figures
Key Terms
reduction in force financial
restructuring charges financial
AUCATZYL net product revenue financial
operational efficiency financial
cash, cash equivalents and marketable securities financial
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What restructuring did Autolus Therapeutics (AUTL) announce in April 2026?
How many employees are affected and when will Autolus complete the workforce reduction?
What cost savings and restructuring charges does Autolus Therapeutics expect?
What 2026 AUCATZYL revenue guidance did Autolus Therapeutics provide?
How long does Autolus Therapeutics expect its cash runway to last?
What benefits will affected Autolus employees receive as part of the reduction in force?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its Charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
| * |
| * | Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.05 Costs Associated with Exit or Disposal Activities.
On April 29, 2026, Autolus Therapeutics plc (the “Company”) announced its Board of Directors approved a plan to improve operational efficiency and reduce operating expenses. This plan will implement a reduction in force whereby the Company will eliminate approximately 13% of the Company’s workforce, inclusive of employee-related actions that began in the second half of 2025.
The Company anticipates that it will complete the implementation of the plan by the third quarter of 2026. Affected employees will be offered separation benefits, including severance payments and, where applicable, temporary healthcare coverage assistance. The Company estimates that it will incur total expenses relating to the realignment of approximately $8 million, consisting of severance and termination-related costs. The Company expects to record a significant portion of these charges in the first half of 2026. The Company has confirmed its financial guidance and is projecting full year 2026 AUCATZYL net product revenue of $120 million to $135 million.
The estimate of costs that the Company expects to incur related to the workforce reduction as well as the decrease in spending, and the timing thereof are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the actions described above.
Item 7.01 Regulation FD Disclosure.
On April 29, 2026, the Company issued a press release announcing the event set forth in Item 2.05. A copy of the press release is furnished as Exhibit 99.1.
The information furnished under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
d) Exhibits
Exhibit No. |
Description of Exhibit | |
| 99.1 | Press Release dated April 29, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements regarding the expected cost-savings from the workforce reduction and the expecting timing for incurring costs associated with the restructuring and related workforce reduction, the expected timing of implementing and completing the restructuring including the workforce reduction. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including, but not limited to, the risk that the Company may not be able to implement the restructuring and the workforce reduction as currently anticipated or within the timing currently anticipated, the impact of the workforce reduction on the Company’s business, the risk that the Company’s cost saving initiatives may not be successful, and unanticipated charges not currently contemplated that may occur as a result of the restructuring. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s subsequent filings with the Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this Current Report on Form 8-K is as of the date of the filing of this Current Report, and the Company undertakes no duty to update this information except as required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AUTOLUS THERAPEUTICS PLC | ||||||
| Dated: April 29, 2026 | By: | /s/ Christian Itin, Ph.D. | ||||
| Name: Christian Itin, Ph.D. | ||||||
| Title: Chief Executive Officer | ||||||
Exhibit 99.1
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
| • | Initiative focused on driving gross profit margin and path to profitability for the ALL business |
| • | Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026 |
| • | Autolus reiterates full year 2026 AUCATZYL® net product revenue of $120 million to $135 million, up from $74 million in 2025, as well as an anticipated shift to positive gross margin in 2026 |
| • | Clinical development programs are on track and include CATULUS, a pivotal Phase 2 trial in pediatric relapsed/refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple sclerosis |
LONDON & GAITHERSBURG, MD, April 29, 2026 — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses. As part of this initiative, the Company is implementing a reduction in force affecting approximately 13% of its workforce. This workforce reduction will impact all areas of the business.
Autolus Chief Executive Officer Dr. Christian Itin said, “With a strong first year of launch in 2025 and good momentum into this year, we are now focused on optimizing our operating model and driving cost efficiency. These actions will enhance our margins, support scalable growth, and position Autolus for long-term value creation. Our team continues to execute at a high level across both commercial and pipeline priorities, and we are encouraged by the meaningful real-world impact AUCATZYL is having for patients. We recognize the impact on the employees affected by these changes and are grateful for their meaningful contributions to our mission.”
The actions are expected to reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027. As a result of the reorganization, which includes employee-related actions taken beginning in the second half of 2025, the Company expects to incur total restructuring charges of approximately $8 million, consisting primarily of employee severance and related costs, the majority of which will be recognized in the first half of 2026. The implementation of the workforce reduction plan is expected to be substantially complete by the third quarter of 2026.
1
Based on current operating plans, including anticipated AUCATZYL net revenues, Autolus continues to expect that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company’s operations into the fourth quarter of 2027.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding Autolus’ future expectations, plans and prospects; anticipated guidance on 2026 AUCATZYL net product revenue; the Company’s anticipated cash runway; the Company’s clinical development plans and timelines; the expected cost-savings from the workforce reduction and the expecting timing for incurring costs associated with the restructuring and related workforce reduction; and the expected timing of implementing and completing the restructuring including the workforce reduction. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including, but not limited to, the risk that the Company may not be able to implement the restructuring and the workforce reduction as currently anticipated or within the timing currently anticipated, the impact of the workforce reduction on the Company’s business, the risk that the Company’s cost saving initiatives may not be successful, and unanticipated charges not currently contemplated that may occur as a result of the restructuring. For a discussion of these risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2026. All information in this press release is as of the date of the release, and the Company undertakes no obligation to publicly update this information, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this press release.
Contact:
Amanda Cray
Executive Director, Investor Relations & External Communications
+1 617-967-0207
a.cray@autolus.com
2